Background: The balance between thrombotic and bleeding risk is of great concern in high
bleeding risk (HBR) patients. This study evaluated the relationship between perioperative …

High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after
percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs …

Objective This meta-analysis aimed to evaluate whether using platelet function testing (PFT)
in acute coronary syndromes (ACS) to personalise antiplatelet therapy including a P2Y12 …

1.1. Purpose The European Society for Vascular Surgery (ESVS) has developed a series of
clinical practice guidelines for clinicians caring for patients with vascular diseases. This is …

This study aims to determine whether CYP2C19 loss‐of‐function (LoF) variants were
associated with long‐term ischemic stroke risk in Chinese primary care patients treated with …

Introduction Dual antiplatelet therapy (DAPT) including prasugrel or ticagrelor is
recommended in patients with acute coronary syndromes (ACS) treated with coronary …

Background Although there is a growing body of evidence that CYP2C19 genotyping can be
beneficial when considering treatment with clopidogrel after percutaneous coronary …

Major bleeding is a common threat in patients requiring antiplatelet therapy. Timing and
intensity with regard to resumption of antiplatelet therapy represent a major challenge in …

Loss‐of‐function (LoF) alleles of cytochrome P450 2C19 (CYP2C19), which are prevalent in
East Asians, are linked to high platelet reactivity (HPR) phenotype and poor prognosis. We …

2 McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
rhesus macaques. Nature 2021; 590: 630–34. 3 Yu J, Tostanoski LH, Peter L, et al. DNA …